Aripiprazole Injection

347 interactions 801 cited references

Also sold as: Abilify Abilify Maintena® Abilify® Aristad Initio® Aristada® Opipza

About Aripiprazole Injection

Aripiprazole extended-release injection (Abilify Maintena, Aristada, Aristada Initio) is used alone or in combination with other aripiprazole preparations to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Aripiprazole ext… Read the full Aripiprazole Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 12, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Mavorixafor Mesoridazine Metoclopramide Pimozide Piperaquine Posaconazole

20 Contraindicated 316 Major 11 Moderate

All (347) Contraindicated (20) Major (316) Moderate (11)

Major

Aripiprazole Injection Protriptyline An increased risk of QT interval prolongation Details Aripiprazole Injection Quazepam Doral An increased risk of sedation and orthostatic hypotension Details Aripiprazole Injection Quetiapine Seroquel An increased risk of QT interval prolongation Details Aripiprazole Injection Quinidine Cardioquin® Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Aripiprazole Injection Quinine An increased risk of QT interval prolongation Details Aripiprazole Injection Quizartinib Vanflyta An increased risk of QT interval prolongation Details Aripiprazole Injection Ranolazine Aspruzyo Increased ARIPiprazole or ARIPiprazole lauroxil (a prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolonga... Details Aripiprazole Injection Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Aripiprazole Injection Relugolix Orgovyx Increased risk of QT interval prolongation Details Aripiprazole Injection Remifentanil Increased risk of CNS depression and an increased risk of hypotension Details Aripiprazole Injection Remimazolam Byfavo Increased risk of profound sedation, respiratory depression, coma, and death Details Aripiprazole Injection Revumenib Revuforj An increased risk of QT interval prolongation Details Aripiprazole Injection Ribociclib Kisqali Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Aripiprazole Injection Rifampin Rifadin Reduced ARIPiprazole exposure Details Aripiprazole Injection Rifapentine Priftin Reduced ARIPiprazole exposure Details Aripiprazole Injection Rilpivirine Edurant An increased risk of QT interval prolongation Details Aripiprazole Injection Risperidone Perseris An increased risk of QT interval prolongation Details Aripiprazole Injection Ritonavir Norvir Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Aripiprazole Injection Ropeginterferon Alfa-2B-Njft Besremi Increased risk of sedation Details Aripiprazole Injection Scopolamine Pamine Increased or potentiated scopolamine effects and an increased risk of CNS depression Details Aripiprazole Injection Selpercatinib Retevmo Increased risk of QT interval prolongation Details Aripiprazole Injection Sertindole An increased risk of QT interval prolongation Details Aripiprazole Injection Sertraline Increased risk of QT interval prolongation and an increased CYP2D6 substrate exposure Details Aripiprazole Injection Sevoflurane Petrem An increased risk of QT interval prolongation Details Aripiprazole Injection Siponimod Mayzent An increased risk of QT interval prolongation Details Aripiprazole Injection Sodium Oxybate Lumryz An increased risk of CNS depression and clinically significant respiratory depression, obtundation, hypotension, profound sedation... Details Aripiprazole Injection Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation Details Aripiprazole Injection Sodium Phosphate, Dibasic An increased risk of QT interval prolongation Details Aripiprazole Injection Sodium Phosphate, Monobasic An increased risk of QT interval prolongation Details Aripiprazole Injection Solifenacin Vesicare An increased risk of QT interval prolongation Details Aripiprazole Injection Sorafenib Nexavar An increased risk of QT interval prolongation Details Aripiprazole Injection Sotalol Betapace An increased risk of QT interval prolongation Details Aripiprazole Injection St John's Wort Reduced ARIPiprazole exposure Details Aripiprazole Injection Sufentanil Dsuvia Reduced pulmonary arterial pressure, increased risk for hypotension, profound sedation, respiratory depression, coma, and death Details Aripiprazole Injection Sulpiride An increased risk of QT interval prolongation Details Aripiprazole Injection Sultopride An increased risk of QT interval prolongation Details Aripiprazole Injection Sunitinib Sutent An increased risk of QT interval prolongation Details Aripiprazole Injection Tacrolimus Astagraf An increased risk of QT interval prolongation Details Aripiprazole Injection Taletrectinib Ibtrozi Increased risk of QT interval prolongation and torsade de pointes Details Aripiprazole Injection Tamoxifen Nolvadex® An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.